83,069 Celcuity, Inc. $CELC Shares Sold by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. cut its stake in Celcuity, Inc. (NASDAQ:CELC – Free Report) by 93.1% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 6,165 shares of the company’s stock after selling 83,069 shares during the period. Jefferies Financial Group Inc.’s holdings in Celcuity were worth $490,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Pictet Asset Management Holding SA lifted its stake in Celcuity by 10,659.7% during the third quarter. Pictet Asset Management Holding SA now owns 291,049 shares of the company’s stock worth $23,144,000 after purchasing an additional 288,344 shares during the last quarter. Integrity Alliance LLC. boosted its holdings in shares of Celcuity by 2.2% in the 3rd quarter. Integrity Alliance LLC. now owns 11,868 shares of the company’s stock worth $944,000 after purchasing an additional 250 shares in the last quarter. Profund Advisors LLC boosted its holdings in shares of Celcuity by 14.2% in the 3rd quarter. Profund Advisors LLC now owns 18,292 shares of the company’s stock worth $1,455,000 after purchasing an additional 2,280 shares in the last quarter. State of Wyoming bought a new position in shares of Celcuity during the 3rd quarter valued at about $251,000. Finally, China Universal Asset Management Co. Ltd. bought a new position in shares of Celcuity during the 3rd quarter valued at about $105,000. 63.33% of the stock is currently owned by hedge funds and other institutional investors.

Celcuity Stock Performance

Celcuity stock opened at $64.37 on Monday. The company has a quick ratio of 14.59, a current ratio of 14.62 and a debt-to-equity ratio of 6.04. The company has a market capitalization of $3.16 billion, a PE ratio of -13.67 and a beta of 0.16. The firm has a fifty day simple moving average of $72.47 and a two-hundred day simple moving average of $98.23. Celcuity, Inc. has a twelve month low of $53.54 and a twelve month high of $151.02.

Celcuity (NASDAQ:CELC – Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($1.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.51) by $0.30. Research analysts expect that Celcuity, Inc. will post -5.01 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Celcuity in a report on Tuesday, September 1st. Citizens Jmp reaffirmed a “market outperform” rating and issued a $177.00 target price on shares of Celcuity in a research note on Monday, August 17th. Wall Street Zen raised Celcuity from a “strong sell” rating to a “sell” rating in a research note on Saturday. Citigroup reiterated a “market outperform” rating on shares of Celcuity in a research report on Monday, November 9th. Finally, Stifel Nicolaus decreased their price target on shares of Celcuity from $175.00 to $150.00 and set a “buy” rating on the stock in a research note on Friday, August 14th. Thirteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $151.79.

Read Our Latest Stock Analysis on Celcuity

About Celcuity

(Free Report)

Celcuity is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company uses its CELsignia platform to analyze signaling activity in tumor cells and identify patients who may be more likely to respond to treatments aimed at specific cellular pathways. Its drug-development program includes gedatolisib, a therapy designed to inhibit PI3K and mTOR signaling pathways. Celcuity is studying the drug in clinical trials for breast cancer and other solid tumors, with a focus on treatment strategies tailored to tumor biology.

See Also

Want to see what other hedge funds are holding CELC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celcuity, Inc. (NASDAQ:CELC – Free Report).

Institutional Ownership by Quarter for Celcuity (NASDAQ:CELC)

Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.